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Abstract
Purpose/Background: The purpose of this quality improvement (QI) project was to increase
Hepatitis C Virus (HCV) screening and identification through the implementation of universal
screening for HCV with a Medical Assistant (MA) workflow as provider prompt. This QI
project evaluated the effectiveness of universal HCV screening in a federally qualified health
center (FQHC), community health center (CHC), patient centered medical home serving
primarily Medicaid, Medicare and uninsured patients. HCV is a major cause of chronic liver
disease throughout the world. It now causes more deaths than any other infectious disease in the
United States (US). Costs associated with its treatment are significant and increasing.
Therefore, early identification through screening and referral to treatment are essential in
preventing the spread of the disease and reducing disease related morbidity and mortality.
Methods: Implementation of universal screening for HCV through an MA driven workflow to
identify the need for screening and as a provider prompt.
Results: The number of HCV at-risk patients screened increased from 1,144 to 1,393, (x2 =
7.96, p = .0048), representing 21.8% increase in the eight weeks post implementation. The
screening rate for all clinic patients increased from 27.1% to 32.2% (x2 = 26.598, p < . 00001).
Additionally, referrals to HCV treatment increased from 314 to 442 (x2 = 5.507, p = .0189),
representing a 40.8% increase.
Conclusion: This MA driven universal HCV screening workflow demonstrated the
effectiveness of a simple, cost-effective practice change in improving the identification of HCV
and referral to treatment.

Keywords: hepatitis C, screening, referral, linkage to care, primary care
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Increasing the Identification of Hepatitis C and Referral to Treatment in Primary Care Through a
Medical Assistant Driven Workflow
Hepatitis C Virus (HCV) infection is a major cause of chronic liver disease in the United
States (US) and throughout the world (Coyle & Kwakwa, 2016; Heil et al., 2018). HCV is
frequently categorized as either acute or chronic. For most individuals, infection with HCV
results in a chronic lifelong illness if left untreated (Centers for Disease Control and Prevention
[CDC], 2018). It is estimated that at least 2.4 million individuals in the US are living with HCV
with infection rates increasing due to the national opioid crisis (CDC, 2018; Oregon Health
Authority [OHA], 2017). Moreover, most individuals with HCV are unaware of their infection
as they remain asymptomatic until advanced liver disease occurs (Coyle & Kwakwa, 2016; Ford
et al., 2018). Early identification of the disease through screening is essential to preventing the
spread of the disease and the referral of individuals to effective treatment to reduce costs to the
healthcare system and save lives. The financial costs associated with chronic HCV to the
healthcare system are significant and increasing. In 2011, the lifetime cost of care for an
individual with chronic HCV was $64,490 while the US spent $6.5 billion on HCV care that year
(Razavi et al., 2013). Deaths from HCV reached record high in 2014, with 19,659 individuals
dying from HCV in the US (Ly, Hughes, Jiles, & Holmberg, 2016). HCV now causes more
deaths than any other infections disease in the US (Ly et al., 2016).
Early identification, referral to effective treatment and quality care are key in fighting the
HCV epidemic (Department of Health of Health and Human Services [DHHS], 2017). Current
HCV screening recommendations from the CDC include: 1) the baby boomer cohort (adults born
between 1945 and 1965); 2) current intravenous drug users; 3) individuals with any history of
injection drug use; 4) individuals with medical conditions which include a history of receiving
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clotting factors before 1987, long-term hemodialysis, long term alanine aminotransferase levels
(ALT), and human immunodeficiency virus (HIV) infection; 5) prior recipients of blood
transfusions or organ transplants; and 6) individuals with a recognized exposure to HCV (CDC,
2015).
A quality improvement (QI) project to increase the screening rates for HCV took place at
a clinic which is a designated healthcare for the homeless clinic, a federally qualified health
center (FQHC), community health center (CHC), and patient centered medical home located in
Portland, Oregon serving approximately 5,000 Medicaid, Medicare and uninsured patients
annually (Central City Concern [CCC], 2016). HCV positive patients are able to receive their
care within the clinic as there is an embedded HCV treatment program.
Clinical Problem
HCV is the most commonly reported blood born virus in both Oregon and the US (OHA,
2017). Furthermore, both chronic HCV and HCV mortality rates for Oregon are over twice that
of the national average (OHA, 2017). Oregon has the third highest chronic HCV rate in the
nation and the second highest mortality rate (HepVu, n.d.; OHA, 2017). In the US, baby
boomers, minorities, injection drug users, individuals living in households with annual incomes
less than $25,000 and those without a high school education are disproportionately affected by
HCV (Coyle & Kwakwa, 2016). As the clinic serves those at the highest risk for HCV in the
community, a robust screening program is essential to help stop the spread of HCV while
ensuring access to treatment and potential cure to minimize the long-term health effects of
chronic HCV such as cirrhosis, liver failure and hepatocellular carcinoma (HCC).
Prior to this project, HCV screening at the clinic was ordered at provider discretion.
Providers receive annual HCV education covering CDC screening recommendations, treatment
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recommendations, and how to refer patients to HCV treatment program in the clinic. It was the
general expectation that those at risk were screened and referred to treatment if appropriate,
however there was no supporting policy or practice guideline. Additionally, there was no
systematic method to ensure screening for at risk patients such as a flag in the electronic health
record (EHR), or through a chart review by the Medical Assistant (MA). Despite knowledgeable
providers and the availability to refer patients to HCV treatment within the clinic, the lack of a
standardized process to ensure HCV screening resulted in a gap in screening those at risk for
HCV. Analysis of baseline data demonstrated only 53% (1,144 of 2,157) of at-risk patients
being screened for HCV. Furthermore, the determination of screening rates for at-risk patients is
limited by EHR reporting. EHR reporting defines those at risk as patients in the baby boomer
cohort and patients with opiate use disorders. When looking at the entire clinic patient
population, only 27% (1,144 of 4,227) of patients are screened for HCV. Due to the
demographic of patients served by the clinic, patients are disproportionately more likely to be at
risk of HCV than the general US public. Therefore, effective screening, diagnosis and referral to
treatment is essential in managing the long-term health needs of the patients as well as helping
prevent further spread of HCV.
Additionally, in working with the HCV program team, clinic care team managers (CTM)
and MA a lack of standardization and training delivering HCV results to patients was identified.
Baseline data analysis along with team member interviews demonstrated that the clinic had
opportunities to improve screening rates for all clinic patients, increase referrals of HCV positive
patients to treatment, to standardize the result notification process by ensuring the most
appropriate team members were providing patients with their results and were trained to do so.
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Through stakeholder engagement, review of current clinic practices and analysis of
baseline HCV data, the project team concluded that the QI project would focus on achieving the
following goals: (1) increase HCV screening of clinic patients; (2) increase referral to HCV
treatment; and (3) standardize the HCV result notification process.
Methods
Project Development
Literature Review
A literature review was conducted searching CINAHL and MEDLINE was conducted
using the search terms: hepatitis C, screening, and primary care with the Boolean connector and.
The review was limited to the years 2013 through 2018 with publication in the English language
only. A five-year timeframe was chosen due to advances in HCV treatment availability.
Twenty-two articles were identified in the initial literature search, one additional article was
found through review of identified articles. Articles were excluded through review, or title,
abstract and full-text review resulting in a total of five articles included in this paper. See
Appendix A: Literature Review Process. The literature review demonstrated that screening in
primary care settings is an effective way to identify HCV (Coyle & Kwakwa, 2016; Ford et al.,
2018; Heil et al., 2018; O'Kelly, Byrne, Naughten, Bergin, & Williams, 2016; Wolffram et al.,
2015). Furthermore, both risk-factor based and universal HCV testing with linkage to care was
shown to be effective in FQHCs and CHCs with similar patient populations as OTC (Coyle &
Kwakwa, 2016; Ford et al., 2018). See Appendix B: Evidence Table and Appendix C: Synthesis
Table.
Theoretical Framework
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The Quality Implementation Framework (QIF) guided project design and implementation
(Meyers, Durlak, & Wandersman, 2012). The QIF was chosen as it provides a structure with
clearly identified steps to follow and key questions to consider at each step throughout all stages
of project design, implementation, and evaluation. Additionally, the QIF provides a large area
on the assessment and preparation steps to ensure the organization is ready for change and build
capacity for change, if needed (Meyers et al., 2012). Lastly, the QIF recognizes that change is a
cyclical process and allows for bi-directional movement within the framework. The project
manager utilized the QIF to ensure key steps were completed during each phase of the project
design, implementation and evaluation process.
Stakeholder Engagement
Clinic providers were surveyed via an online survey distributed through email asking the
following questions: (1) Do you screen all patients for HCV? (2) If not, how do you determine
who to screen?, (3) What barriers do you have with screening your patients for HCV?, and (4)
What would make it easier for you to screen your patients for HCV?. Providers reported barriers
to HCV screening including the inability to confirm patient’s HCV screening status,
unfamiliarity with screening recommendations, unfamiliarity with HCV screening labs, lack of
time, and other priorities. Providers frequently have to comb through past medical records to
find screening results, a time-consuming task. Additionally, patients frequently recall neither
past screening nor past behaviors that put them at risk of contracting HCV. MAs and CTMs
were interviewed from each care team within the clinic to identify challenges with screening and
seek feedback as how to improve the process.
Screening Workflows
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Based on recommendations from the literature, the HCV team and clinic leadership
supported moving to a model of universal HCV screening with annual screening for patients with
ongoing risk factors, such as IV drug use. The clinic is well situated to have a positive impact on
HCV rates and treatment outcomes due to its ability to identify HCV in a high-risk population
group through universal screening and subsequently link them to treatment with the embedded
HCV program. While the CDC recommends screening patients in high risk groups, in Oregon
half of all new HCV infections occur in persons 30 years of age or younger (OHA, 2017).
Therefore, a universal screening program which offers one-time screening to all clinic patients
and annual screening for those at continued risk will help to ensure identification of those with
HCV infection. Through referral of patients who test positive for HCV to the embedded HCV
program, access to effective care can be ensured, helping to prevent new infections and decrease
HCV mortality in Oregon. Clinic providers, CTMs and MAs agreed that adding HCV screening
status to the clinic’s “huddle prep process” would be an effective method to identify the need for
screening.
Huddle Prep Process
Prior to all patient visits, MAs prepare for the visit by using a huddle prep document. See
Appendix D: HCV Huddle Prep and Resource Initial. Through this review MAs are able to
prompt providers for necessary screenings and procedures, such as a capillary blood glucose
(CBG) or hemoglobin A1C lab draw for diabetics, or HIV screening. Portions of the necessary
info for huddle prep pull into the EHR for MAs to review, but other key sections do not, such as
HCV screening status. The Huddle Prep document was revised with Clinic Operations Manager
and MA input to better reflect the actual workflow of MAs as to how they navigate within the
EHR. Components of huddle prep were grouped to correspond with where the information is
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found in the EHR. See Appendix E: HCV Huddle Prep and Resource Final. All clinic MAs
were trained through an MA staff meeting and individual follow-up by clinic operations
manager. Additionally, all MA’s completed a competency assessment of their ability to find the
information listed on the HPRD in the EHR and provider notification of their findings to allow
the provider to consider screening if appropriate.
Result Notification Workflows
In addition to adjusting the MA workflow to prompt screening, the team standardized the
result notification process by having health assistants notify patients of negative results, and
CTMs notify patients of positive results and schedule follow-up care simultaneously. See
Appendix F: Result Notification Process. CTMs were trained on the positive result notification
process and HCV counseling by the project coordinator at a team meeting using
recommendations form the CDC and the Harm Reduction Coalition (CDC, n.d.; Ellendon, 2003).
Project Implementation Timeline
Project development utilizing provider, MA and CTM interviews along with huddle prep
form revisions and trials occurred in September and October of 2018. The project was proposed
and approved by the HCV program team in early November 2018. CTM training on the new
HCV result notification process was completed in November of 2018. MA training and
competency validation on the revised huddle prep process was completed in December 2018.
The revised huddle prep process using the new huddle prep document was implemented midDecember 2018. See Appendix D: HCV Huddle Prep and Resource Final.
Data Collection and Evaluation
Both process and outcomes measures were tracked to measure efficacy of the project.
Process measures included MA and CTM training completion rates. Outcome measures tracked
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were screening rate of at-risk patients, screening rate of all clinic patients and number of referrals
to HCV treatment. Training and competency completion rates were gathered upon
implementation by the project manager and clinic operations manager using competency
validation forms. Eight weeks post implementation, HCV screening and referral numbers were
gathered and compared to baseline data. Due to reporting challenges the total number of
screenings and referrals were tracked and compared to the baseline data, rather than using
screening and referral rates over separate timeframes. A chi square analysis was conducted to
determine the association between the new screening workflow and the increase in HCV
screening for both at risk and all clinic patients. Chi square analysis was completed using Social
Science Statistics (Stangroom, 2019).
Ethical Considerations
Institutional Review Board (IRB) approval was sought and granted for this project by the
University of Portland IRB committee. Informed consent to allow their training and competency
data to be included in the project outcomes was reviewed with MAs and CTMs to include their
competency and training data in the results of this project. Patients maintained the right to refuse
HCV screening and/or referral to treatment. All project team members were free from relevant
conflicts of interest.
Results
Project outcomes were tracked using a metric tracker table. See Appendix G: Metric
Tracker for more detail. All 19 clinic MAs competed the huddle prep training and competency
validations and all six clinic CTMs completed the HCV counseling training. The number of
active patients, defined as patients who saw a provider at least once in the last two years,
increased during the project timeframe from 4,227 to 4,332, an increase of 2.2%. Furthermore,
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the number of patients at risk for HCV at the clinic increased from 2,157 to 2,436, representing a
12.9% increase (x2= 23.30 p < .00001). The number of at-risk patients screened increased from
1,144 to 1,393, representing 21.77% increase (x2 = 7.96, p < .004787). The screening rate for all
clinic patients increased from 27.06% to 32.16% (x 2= 26.60, p < .00001). Additionally,
referrals to HCV treatment increased from 314 to 442 (x2 = 5.51, p = .0189), representing a
40.8% increase. The screening rate of all clinic patients increased more than the rate of HCV atrisk patients, and 18.9% increase as compared to a 7.8% increase.
Discussion
These findings suggest that the MA driven workflow to prompt provider consideration of
the need for HCV screening using a model of universal screening was successful in increasing
screening for both patients identified as at-risk for HCV and those who were not defined as at
risk of HCV per CDC recommendations. The project was optimistically accepted by clinic staff,
providers, and patients. As anticipated, the project proved effective in increasing screening for
both patients identified as at-risk and those who were not, and resulted in an increase in referrals
to treatment. Moreover, the rate of increase in referrals rose at a steeper rate than the increase in
both patients identified at risk, and patients screened, indicating increasing rates of patients
identified as having HCV. Screening of patients not traditionally deemed as at-risk is known to
be effective in identifying chronic HCV as not all patients accurately recall or disclose their atrisk behaviors (Coyle & Kwakwa, 2016). The project data is consistent with this finding as the
total screening rate and referrals to treatment both increased at a higher rate than the HCV at-risk
screening rate.
Project Limitations
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Due to EHR and reporting limitations it was not possible to gather HCV screening,
identification and referral rates for discontinuous timeframes. Therefore, all data was analyzed
beginning February 1, 2017. February 1, 2017 was chosen as the HCV treatment program began
at that time resulting in HCV program data available for the total timeframe between February 1,
2017 and the end of the project data collection timeframe, but not at different intervals.
Additionally, current EHR reporting does not fully identify all HCV risk factors. A patient is
only classified as at-risk if they are in the baby boomer age cohort and if they have “problem”
history of opiate use disorder. Therefore, the data analysis does not fully capture all patients at
risk for HCV.
Additionally, the data collection timeframe was limited to eight weeks. During this
timeframe, HCV screening was fresh in the minds of both MAs and providers. Ongoing
evaluation of the project will need to be done by the clinic operations manager and HCV
program team to continue to assess ongoing effectiveness in increasing HCV screening and
referrals as a proxy for HCV infection.
EHR changes to support more rapid identification of HCV screening needs, such as
clearer identification of risk factors, pulling in HCV screening status to the EHR huddle prep,
along with improved reporting would have allowed for cleaner data analysis in both the
gathering of baseline data and post-practice change data.
Lessons Learned
This QI project proceeded smoothly as designed with outcomes as expected. Utilizing
the QIF, engaging stakeholders early, identifying potential barriers and developing mitigation
strategies for those barriers allowed for a successful project which can be sustained utilizing the
clinic’s existing structures.
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Conclusion
HCV screening has been demonstrated to be cost-effective as the early identification and
treatment of HCV decreases the overall economic burden to the individual and health system
through the prevention of healthcare related costs and potential disability from liver disease
(Joshi, 2014). The current project, intentionally designed to be embedded within current clinic
structures and workflows at no organizational cost and requires no ongoing additional resources
in terms of committee structures, time, or staffing for sustainability. Clinic HCV data will be
tracked moving forward by the HCV team program coordinator and standard clinic quality
assurance processes. The revised MA huddle prep process proved to be a cost-effective means to
improve HCV identification and linkage to treatment, thus improving the health of clinic patients
and the community overall.
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Appendix B: Evidence Table
Citation
(author,
title,
year)

CF
or
TF

Study
Design/
Method

Setting/
Sample

Coyle, et
al. Pub
Hlth Rep
2016:
131(S1)
41-52

Non
e

Multicenter,
prospective
study

4
CHC/FQHCs
in
Philadelphia,
PA caring for
low-income
and homeless
patients

• MA
initiated
routine
HCV and
opt-out
HIV
testing for
all CHC pt
with
known
risk
factors
and/or
baby
boomer
cohort
• Team and
provider
training
• Linkage to
ongoing
care and tx

n = 9035
≥ age 18 pt
unaware of
their HCV or
HIV status

Major
Variables
(and their
definition
s)
IV –
routine
HCV and
opt-out
HIV
testing
DV – pts
screened
for HCV
and HIV

Metrics

Data
Results
analysis
(stats)

Strengths
Limitations
Applicability

# pt
tested for
HCV

%ages,
no
statistic
al
analysis

Strengths:
• Multiple test sites with
experience working with
and tx pt at high risk for
HCV
• Free testing
• Diverse pt sample in
terms of gender, race
• Include both pt and
provider education
• Used reflexive testing to
prevent additional lab
draws
• Demonstrated efficacy
and feasibility of opt-out
HCV and HIV screening
as part of routine
primary care

# pt
tested for
HIV
%
increase
of HCV
and HIV
testing
after
implemen
tation of
routine
testing
# pts antiHCV +
# pt
received
RNA

Post
implementatio
n:
• 1,888 pt
tested for
HCV
• 3,890 pt
tested for
HIV
Representing
a:
• 23.7%
increase in
HCV testing
• 124.7%
increase in
HIV testing
Testing
Discovered:
• 101 HCV +
pt
• 13 HIV + pt

Limitations:
• No statistical analysis to
determine if outcomes
were statistically
significant changes
• During study timeframe,
two test sites moved to
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for those
who test
positive

19

confirmat
ory test

Linkage to
Care for:
• 39 HCV +
pt
• 9 HIV + pt

# pt with
chronic
HCV
infection
# pt HIV
+

Ford, et
Non
al.,
e
JPHMP
2018;
24(1) 4148

Multicenter,
prospective
study
• Targeted
outreach
with rapid
HCV ab
screening
in the field

12 test sites
comprised of:
• 6 CHCs
• 4 FQHCs
• 2 SEPs
In lowincome
neighborhood
s of NYC
with high

IV –
targeted
outreach
to
encourage
rapid HCV
screening
DV –
• Pts
screene

# pts antiHCV +
# pt
received
RNA
confirmat
ory test
# pt with
chronic

%ages
for
outcom
es
%ages
with
95% CI
for pt
demogr
aphics

880 (19%) pt
anti-HCV ab
positive
Of, anti-HCV
ab + pts 678
(77%)
received RNA
confirmatory
testing

universal HCV
screening for all clients
due to high rates of
HCV outside of the baby
boomer birth cohort and
known risk factor pts
Applicability:
• Applicable to OTC due
to:
• Similar pt populations
served
• All test sites were
CHC/FQHC like OTC
• Demonstrates
importance of
screening with
confirmatory testing,
linkage to care and
availability of tx in
one site, which OTC
has
Strengths:
• Numerous test sites with
experience working with
and tx pt at high risk for
HCV
• Free testing
• Diverse sample in terms
of gender, race and
testing site
• Used rapid HCV ab
testing in the field
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• Lab draw
for
confirmato
ry testing
• Pt
navigators
for linkage
to care
• Medical
provider
training

rates of HCV
infection
n = 4751

d for
HCV

HCV
infection
# chronic
HCV pt
with
linkage to
care
# chronic
HCV pt
who are
tx
candidate
s
# chronic
HCV pts
who
initiated
tx

20
and
testing
site
Chi
square
test to
assess
differen
ce
between
pt who
received
confirm
atory
testing
and
those
who did
not

Of the 678
• Include both pt and
seropositive pt,
provider education
512 (76%) had
chronic HCV
Limitations:
infection
• Did not include total #
pts outreached to
435 (85%) pt
• No CI analysis for
with chronic
outcomes
HCV had
• Included pts who
linkage to care
already knew HCV
positive status
Of pt who
• At the time of the study
were linked to
tx restrictions included
care, 47 (30%)
fibrosis levels and active
were deemed
IV drug use – these are
tx candidates
no longer in place
14 pts (30) of
those deemed
tx candidates
initiated tx

Applicability:
• Applicable to OTC due
to:
• Similar pt populations
served
• 10 of the test sites
were CHC or FQHCs.
OTC is both a CHC
and FQHC
• Demonstrates
importance of
screening with
confirmatory testing,
linkage to care and
availability of tx in
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Heil, et
Non
al., Ann e
Fam
Med
2018;
16(1) 2127

Multicenter,
prospective
study
Invited pts
between age
40 and 70 to
participate in
HBV and
HCV testing
over a 3-day
period for no
charge
Screening
testing
covered
HBV and
HCV
antibodies.
If screening
+, blood sent
for
confirmatory
testing

11 family
practices is
the
Netherlands
serving 2
areas of high
HVC
prevalence
n = 6743

IV –
invitation
of HBV
and HCV
testing to
all pts
between
age 40 –
70 at
primary
care
clinics
DVs
• Pt opt
in to
testing
• Pt opt
out of
testing

Total test
uptake (#
pt who
tested)
# positive
tests for
HBV
# positive
tests for
HCV

21

%ages
with
95% CI

3,434 (50.9%)
[95% CI =
49.7% to
52.1%] opted
in to HBV and
HCV testing
0 active HCV
infections
7 past HCV
infections
9 active HBV
infections
• 2 known
diagnoses
• 7 new
diagnoses
142 past HBV
infections

one site, which OTC
has
Strengths:
• Simple implementation
strategy
• Testing was free
• High test uptake
• Demonstrated efficacy
of primary care/public
health approach to
HBV/HCV screening
• First study assessing
public health/primary
care testing strategy in
Europe
• Demonstrated
importance of birth
cohort screening in
addition to risk factor
prevalence
Limitations:
• Did not rule out
selection bias as HCV
pts tend to have lower
health literacy, a letter
outreaching for testing
may not be effective
• Risk factor data for
HBV and HCV reported
by pt may be inaccurate
due to recall bias or
social desirability bias
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• No questions on sexual
risk factors were
included in
questionnaire
• Lack data pts who did
not test
• Data from pts who did
not test may not be
generalizable to general
public

O’Kelly,
et al., Br
J Gen
Pract
2016;

Non
e

Multicenter,
prospective
study

Four primary
care centers in
Dublin
Ireland
serving an

IV - offer
of BBV
testing to
all adult
pts who

# pt opt in %ages
to BBV
with
testing
95% CI

1063 (89.5%)
[95% CI =
87.7% to
91.2%] opted

Applicability:
• Applicable to OTC due
to:
• Primary care setting
• Known HCV hot spot
• Implementation
through provider
invitation to testing
• No adjustment to EHR
needed
• Suggested that testing
be done as part of
routine lab work to
increase test uptake,
rather than having a pt
come in for solely
HBV and HCV testing
Strengths:
• Simple implementation
strategy with education
of all pertinent care team
members
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66(647):
e392396

Offered BBV
testing to all
adults age 18
and over who
presented to
the sites for
routine blood
tests over a
six-month
period.
BBV testing
screened for
HBV surface
antigens,
HCV
antibody, and
HIV antigenantibody
combination.

Wolffra
m, et al.,
J
Hepatol
2015: 62

Non
e

Multicenter,
prospective
study

impoverished
area.
n = 1188 pts

present for
routine
blood
testing

# pt opt
out of
BBV
testing

Represented
8% of
practice
populations.
• 753 female
• 453 male
• Median age
= 54

DVs
• pt opt in
to BBV
testing
• pt opt
out of
BBV
testing

# positive
tests for
HBV

23
in to BBV
testing
125 (10.5%)
opted out of
BBV testing
10 pt had
positive results

# positive
tests for
HCV

2 new
diagnoses of
HBV

# positive
tests for
HIV

2 new
diagnoses of
HCV
0 new
diagnoses of
HIV

51 primary
care private
practices in
Germany

IV:
• include
ALT,
HBsAG
, and

# HBsAg
+ pts
# antiHCV + pt

T test
with
Welche
s
approxi

20,864 pts
screened for
HBV

• Educational hand outs
and signs for pts
• High rate of pts who opt
in confirms that opt-out
testing for BBV is viable
in primary care
• Adds to limited existing
literature regarding optout BBV screening in
primary care
Limitations:
• Relatively small study
with four study sites
• Limited number of pts
• Conducted over short
time-frame (six months)
Applicability:
• Quite applicable to OTC
due to:
• Primary care setting
• Impoverished area
• Implementation
through care team and
pt education
• No adjustment to EHR
needed
Strengths:
• Large sample size
• Large testing uptake
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Implemented
routine ALT,
HBV and
HCV testing
as part of
Check Up
35+, a
standard
preventative
medical
exam for pt
who are at
least 35 and
is covered by
insurance
along with a
16-question
questionnaire
assessing
risk factors
for HCV and
HBV

n = 21,008
with an avg of
412 pt at each
practice
780 pts were
<35 and
included in
study
Mean age –
57.5 years
11,766 (56%)
female
2,740 (13.9%)
pt were
immigrants

antiHCV
# pt with
testing
elevated
in
ALT
routine
lab
work of
CheckUp 35+
• 16
question
pt
question
naire
assessin
g risk
factors
for
HCV
and
HBV
DV –
pts opt out
of testing

24
mation
to
compar
e the
two
means
Odd
ration
with
95% CI
testing
for risk
factors
identifie
d by
question
naire

20,917
screened for
HCV
Prevalence
rates as
follows:
• HBsAG –
0.52%
• Anti-HCV –
0.95%
• HCV-RNA
– 0.43%
Infection
previously
unknown in:
• 85% of
HBV + pt
• 65% of
HCV + pt
Risk factors
most
associated
with HBV:
• Immigration
(4.4 [2.9,
6.7])
• Infection in
household
(2.5 [1.2,
4.5])

• Thorough statistical
analysis of pt
demographics and risk
factors associated with
HBV and HCV infection
• First prospective study
evaluating routine HBV
and HCV testing in
primary care in
Germany
• Identified a higher
disease burden than had
been previously
described by the national
health authority
Limitations:
• Age distribution of
sample not
representative of
German population
• Sample size likely didn’t
include a representative
number of high-risk
patients
• Data on study
participation rates not
collected
Applicability:
• Applicable to OTC due
to:
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• Male gender
(1.6 [1.1,
2.4])
Sexual risk
factors for
HBV
underreported
Risk factors
most
associated
with HCV:
• IV drug use
(384 [233,
644])
• Blood
transfusion
before 1992
( 5.3 [3.57.9])
• Immigration
(2.4 [1.5,
3.6])

• OTC’s patient
population contains
patients identified at
high risk with this
study
• Demonstrates ability
to complete routine
HCV and HBV testing
in a primary care
setting with a large
sample size

Notes: % = percent, + = positive, ab = antibody, ALT = alanine aminotransferase, BBV = blood borne virus, CF = conceptual
framework, CHC = community health center, CI = confidence interval, DV = dependent variable, EHR, electronic health record,
FQHC = federally qualified health center, IV= independent variable, HBsAG = hepatitis B surface antigen, HBV = hepatitis B virus,
HCV = hepatis C virus, HIV = human immunodeficiency virus, MA = medical assistant, NYC = New York City, New York, USA, pt
= patient, SEP = syringe exchange programs, TF = Theoretical framework, tx = treatment
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Appendix C: Synthesis Table
Study
Citation
Coyle, et al.
Pub Hlth Rep
2016:
131(S1) 4152

Population
& Number
of
Participants
Pts served by
4
CHC/FQHCs
in lowincome areas
of
Philadelphia,
PA

Duration
of Study

Study
Design

Intervention

9 months
Multicenter, Implementation
(9/1/2013 prospective of MA driven
–
routine HCV
5/31/2014)
and opt-out
HIV testing as
part of primary
care visits

n = 9035

Ford, et al.,
JPHMP
2018; 24(1)
41-48

≥ age 18 pt
unaware of
their HCV or
HIV status
Pts served by 1 year
6 CHCs, 4
(May
FQHCs, and 2012 –
2 SEPs in
Apr 2013)
high HCV
prevalent
areas of
NYC
n = 4751

Impact of Intervention and
Recommendation

Level of
Evidence

HCV Screening ⇑
HIV Screening ⇑⇑

Level 4

HCV Diagnosis ⇑⇑
HIV Diagnosis ⇑
HCV Linkage to Care ⇑⇑
HIV Linkage to Care ⇑
Universal screening for HCV/HIV as part
of routine primary care with opportunity
to opt out

Multicenter, Rapid HCV
prospective screening with
availability for
confirmatory
testing, linkage
to care and tx

HCV ab + ⇑⇑⇑⇑
HCV infection confirmation ⇑⇑⇑
HCV linkage to care ⇑⇑
HCV tx initiated ⇑
Universal screening for HCV with
availability of co-located care navigation,
and HCV tx

Level 4
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Heil, et al.,
Ann Fam Med
2018; 16(1)
21-27

Pts age 403 testing
70 in 11
days over
family
8 months
practices in 2
known HCV
hot spots of
the
Netherlands
personally
invited to
come in
HBV and
HCV testing
by PCP
n = 6743

O’Kelly, et
al., Br J Gen
Pract 2016;
66(647):e392396

Adult pts in
Six
primary care months
centers in
Dublin,
Ireland who
presented for
routine blood
screening
n = 1188

Wolffram, et
al., J Hepatol
2015: 62
1256-1264

51 primary
care private
practices in
Germany

16 months

Multicenter, PCP personal
prospective invitation to pts
between age 40
and 70 to come
in for free
HBV and HCV
testing on one
of three testing
days.
Pt who did not
show for
testing after
initial
invitation were
sent reminder
invitations
Multicenter, Offer BBV
prospective testing which
included HBV,
HCV, and HIV
screening to all
adult pts who
presented for
routine blood
testing

Multicenter, Included ALT,
prospective HBsAG, and
anti-HCV ab
testing in the

27
HBV/HCV test uptake ⇑⇑⇑

Level 4

HCV Diagnosis ⇑
HBV Diagnosis ⇑⇑
Birth cohort testing in addition to risk
factor prevalence for HBV and HCV
Suggested that testing with routine blood
work would be more effective than having
pts come in solely for HBV and HCV
testing

BBV opt in to testing ⇑⇑

Level 4

HBV Diagnosis ⇑
HCV Diagnosis ⇑
HIV Diagnosis 
Implement opt-out screening for BBV in
primary care
HBV Screening ⇑
HCV Screening ⇑

Level 4
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n = 21,008
with an avg
of 412 pt at
each practice
780 pts were
<35 and
included in
study

Check-Up 35+
annual visit
along with a
16-question
questionnaire
focusing on
risk factors for
HBV and HCV

28
HBV Diagnosis ⇑⇑
HCV Diagnosis ⇑
Include HBV and HCV screening as part
of routine primary care visits with the
ability to opt-out

Mean age –
57.5 years
11,766
(56%)
female
2,740
(13.9%) pt
were
immigrants
Notes: ab = antibody, BBV, blood-borne virus, HBsAg = hepatitis B surface antigen, HBV = hepatitis B virus, HCV = hepatis C
virus, HIV = human immunodeficiency virus, MA = medical assistant, NYC = New York City, New York, USA, PCP = primary care
provider, pt = patient tx = treatment
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Appendix D: HCV Huddle Prep and Resource Initial
Test

frequency

Male

Female

Diabetic

SBIRT
PHQ 3
PHQ 9
CBG
A1C

Initial visit and annual

x
x
x
x
x

x
x
x
x
x

x
x

x
x
x
x
x
x
x

x
x
x
x
x
x
x
x
x

x
x

x
x

x

x

x

x
x

x
x

x
x

Foot exam
UA urine dip
Eye referral
Flu vaccine
Pneumococcal
Pap
Mammogram
Colonoscopy
Fit kit
TSH
TDaP
Last pain Rx/last
UDS? Evaluate refill
potential (28 day)
Pain medication
orders
Open orders
Effective
contraceptive use
Hep C
HIV

Initial visit and when PHQ 3 is +
Controlled q 6 months
Uncontrolled q 3 months
Annual
Annual
Annual
Annual
One dose
Q 3 years
Q 2 years
Once (unless abnormal)
annual
Annual if normal, q 6 m if
abnormal
Q 10 years

Annually and q visit if not on
problem/med list
Once and prn risk factors
Once and annually with risk
factors

50-74

18-50

65+

smoker

x

x

x
x
x

x
x
x

24-64

x
x

x
x

x
x

x
x
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Appendix E: HCV Huddle Prep and Resource Final
Task/Test
Print provider schedule
Reason for appointment
Pop ups/behavior agreements
Interpreter Needed
VACCINES:
Flu vaccine
Pneumococcal
TDaP
CENTRICITY HUDDLE
INFO:
Open orders
Hep C test
SBIRT
A1C
Foot exam
Urine microalbumin/creat
Eye referral
Pap
Mammogram
Colonoscopy
Fit kit
Problem/Med List:
Injections/LAI due
CBG
Effective contraceptive
use**
Dx of COPD: oxygen level
LABS:
Last UDS
HIV test

Frequency

Male

Female

Every visit
Every visit
Every Visit

x
x
x

x
x
x

Annual
One dose
Q 10 years

x
x
x

x
x
x

Every visit
Once and annually with risk
factors
Initial visit and annual
Controlled q 6 months
Uncontrolled q 3 months
Annual
Annual
Annual
Q 5 years
Q 2 years
Once (unless abnormal)
Annual

x
x

x
x

x
x

x
x

x
x
x

x
x
x
x
x
x
x

Every visit
Every visit
Annually or with each visit
if not on problem/med list
Every visit

x
x

x
x
x

x

x

Every visit
Once and annually with risk
factors

x
x

x
x

x
x

Diabetic

50-74

18-50

x

65+

smoker

x

x

Opiate
RX/Use

x
x
x
x
x
x
x
x

24-64

x

x
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Appendix G: Metric Tracker
PreImplementation

PostImplementation

Percent Change

MA competency
validation rate

0

100%

CTM training
completion rate

0

100%

Total Number of
Clinic Patients

4227

4332

2.2%

Identified HCV AtRisk Patients

2157

2436

12.9%

Patients Not
Identified as HCV
At-Risk

2070

1896

-8.4%

Patients Screened

1144

1393

21.8%

Identified HCV AtRisk Patients
Screening Rate

53.0%

57.2%

7.8%

Total Clinic HCV
Screening Rate

27.1%

32.2%

18.9%

Referrals to HCV
Treatment

314

442

40.8%

